Unique Quantitative Diagnostic System Enables Immediate Diagnosis and Treatment at POC

The use of rapid diagnostic tests has markedly expanded in recent years, primarily serving as an initial step by offering qualitative results. Now, a unique diagnostic system that offers both qualitative and quantitative results could allow healthcare providers to receive an immediate diagnosis, making it a truly point-of-care solution for the on-the-spot treatment of patients.

MedMira Inc.’s (Halifax, NS, Canada) rapid multiplexed quantitative diagnostic system offers a total solution from screening to confirmation to monitoring disease progression. The novel diagnostic system allows for accessible and efficient diagnostic tools for quantitative results in minutes. Its user-friendly interface combined with automated interpretation allows for the expansion of MedMira's current Rapid Vertical Flow Technology (RVF) based diagnostic tests and can provide a pathway to significantly increase the technology's multiplexing abilities. The combination of the RVF and Surface-Enhanced Raman Spectroscopy (SERS) technology creates MedMira's novel high-quality and cost-effective tool for the next generation - MIROQ.

Image: MedMira has received a Canadian patent for its unique quantitative diagnostic system (Photo courtesy of MedMira)

MIROQ significantly amplifies the results of MedMira’s RVF-based rapid tests by generating a distinctive 3D structure with remarkable reproducibility that is yielded in a linear plot (R2 = 0.98). This will allow MedMira to expand its access in both the clinical immunoassay and the Point-of-Care markets, opening new doors into the evolving diagnostic landscape by providing both qualitative and quantitative test results in minutes. The synergies between both the technologies allow MedMira to provide a highly effective and affordable alternative to the current costly and time-consuming screening and monitoring systems. MedMira has received a Canadian patent for its new innovative and quantitative test system, in addition to the U.S. patent received in 2022.

"All our rapid tests are based on MedMira's patented RVF Technology and provide an immediate quality Yes or No answer(s). Our speed in addition to our unique control line, allow for the fastest and high-quality answer(s) at a real Point-of-Care setting. While the use of rapid tests has significantly increased over the last years, rapid tests are the first step by providing qualitative result(s). MedMira's vision is to expand this further by adding a unique value to its MIROQ system. The Company's RVF Technology together with the MIROQ technology allows health care providers to receive an immediate diagnosis with both qualitative AND quantitative results." said Hermes Chan, CEO of MedMira Inc. "The synergies of both systems provide the highest quality answers within in minutes and at the most economical costs for health care providers. This combination allows for a truly Point-of-Care situation and enables for immediate treatment of patients. Our future vision has already become reality with MIROQ."